*Davies C, Pan H, Godwin J, et al, for the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.* Lancet *2012; published online Dec 5. http//:www.dx.doi.org 10.1016/S0140-6736(12)61963-1*---In this Article (published online Dec 5), the number of ischaemic heart disease events in the stop tamoxifen at 5 years group should have read "163" not "63" in table 2. In the figure legends on each of pages 14--18 of the appendix, "ER unknown" and "definitely ER+" should have been transposed. Finally, the investigators inadvertently omitted two of the 38 authors, two of the thousand collaborators, and the entire list of collaborating centres (appendix pp 50--53). The report and appendix have been amended to reflect these changes. These corrections have been made to the online version as of Feb 11, 2013, and will be made to the printed Article.
